title: Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.
abstract: BACKGROUND
  The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.
  
  
  METHODS
  We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.
  
  
  CONCLUSIONS
  This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab.
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Katherine
authors.initials: K
authors.lastname: Linder
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Deepthi
authors.initials: D
authors.lastname: Gandhiraj
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Madhura
authors.initials: M
authors.lastname: Hanmantgad
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Seiter
authors.affiliation: Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595 USA.
authors.forename: Delong
authors.initials: D
authors.lastname: Liu